North America Anti-Viral Therapies Market to Grow at a CAGR of 8.5% to reach US$ 31,092.80 Million from 2020 to 2027

The North America anti-viral therapies market is expected to reach US$ 31,092.80 million by 2027 from US$ 16,312.45 million in 2019; it is estimated to grow at a CAGR of 8.5% from 2020 to 2027.

Increasing R&D expenditures in pharmaceutical companies and rising government support for research activities and clinical trials are the key factors driving the growth of the anti-viral therapies market in the region. However, the high cost of drug development is the major factor hindering the market growth.

Antiviral therapy is one of the most exciting branches of virology. These therapies are based on several strategies—direct-acting antivirals target viral proteins, enzymes, or nucleic acids; passive antibodies neutralize circulating viruses; and several other antivirals target cellular proteins or processes essential for viral replication.

Increasing prevalence of chronic viral infectious diseases, such as hepatitis, AIDS, and viral influenza; and emergence and re-emergence of new viral infections, such as diseases caused by coronavirus and picornaviruses, have boosted the demand for novel antiviral therapeutic strategies. The molecular mechanism of viral infection is a field with huge potential for the development of new antiviral drugs or agents that target viral proteins or host factors. The antiviral therapies or agents are used stand-alone or in combination with other drugs to control the viral diseases. Earlier, in the clinical trials, a drug combo already used against HIV in. In addition, during the World War II, a malaria treatment first tested, and in 2019, a new antiviral launched that promise against Ebola fizzled. Further, in 2020, Gilead Sciences initiated two Phase-3 studies of investigational antiviral Remdesivir for the treatment of COVID-19.

North America has been witnessing growing number of COVID-19 cases since its outbreak. In the US, the FDA has approved the emergency-use authorization of experimental drugs. Clinical trials of Remdesivir, monoclonal antibodies, interferons, ACE inhibitors, and hydroxychloroquine have all been registered in the US. Further, American pharmaceutical companies are taking tremendous efforts to develop drugs and vaccines for the COVID-infected patients. AbbVie, Harbour BioMed (HBM), Utrecht University (UU), and Erasmus Medical Center (EMC) have collaborated to develop a novel therapeutic antibody to prevent and treat COVID-19.  Thus, the rising incidence of COVID-19 is escalating the demand for antiviral drugs in North America.

Mexico Anti-Viral Therapies Market, Revenue and Forecast to 2027 (US$ Million)

NORTH AMERICAANTI-VIRAL THERAPIES MARKET SEGMENTATION

By Type

• Branded Drugs
• Generic Drugs

By Mechanism of Action

• Nucleotide Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Others

By Application

• HIV
• Hepatitis
• Virus Influenza
• Herpes
• Others

By Country

• US
• Canada
• Mexico

Company Profiles

• Abbott
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Johnson and Johnson Services, Inc
• Merck & Co., Inc
• Gilead Sciences, Inc.

North America Anti-Viral Therapies Report Scope